BeOne Medicines

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• ONC Maintained by JP Morgan -- Price Target Raised to $445 (öffnet in neuem Tab)

  GuruFocus · 01.10.2026

• BeOne Medicines (NASDAQ:ONC) Stock Price Target Raised at JPMorgan Chase & Co. (öffnet in neuem Tab)

  MarketBeat · 01.10.2026

• BeOne Medicines price target raised to $445 from $425 at JPMorgan (öffnet in neuem Tab)

  TipRanks · 01.10.2026

• Biotech Leader BeOne Medicines Poised To Hit Early Buy Points (öffnet in neuem Tab)

  Investor's Business Daily · 01.10.2026

• BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock Has Consensus Target Price of $402.71 (öffnet in neuem Tab)

  MarketBeat · 01.10.2026

• Form 144 BEONE MEDICINES LTD. For: 1 October By Investing.com (öffnet in neuem Tab)

  Investing.com Canada · 01.10.2026

• Form 4 BeOne Medicines Ltd. For: 1 October By Investing.com (öffnet in neuem Tab)

  Investing.com Canada · 01.10.2026

• BeOne Medicines (NASDAQ:ONC) Insider Sells $11,318,704.12 in Stock (öffnet in neuem Tab)

  MarketBeat · 30.09.2026

• After exercising options, BeOne Medicines (ONC) scientific advisory chair sold 31,028 depositary shares. (öffnet in neuem Tab)

  Stock Titan · 30.09.2026

• An officer proposes selling $407K in vested stock grants at BeOne Medicines (ONC). (öffnet in neuem Tab)

  Stock Titan · 30.09.2026

• BeOne Medicines Ltd (6160) Receives a Buy from DBS (öffnet in neuem Tab)

  The Globe and Mail · 29.09.2026

• BeOne Medicines Advances BGB-58067 Tablet Study, Sharpening Early-Stage Investor Focus (öffnet in neuem Tab)

  TipRanks · 28.09.2026

• Josh Schwartz Marks His Final Day at BeOne Medicines (öffnet in neuem Tab)

  Oncodaily · 27.09.2026

• BeOne Medicines (ONC) Rebrand Puts Its Growth Story In Focus On A Higher Fair Value (öffnet in neuem Tab)

  Simply Wall Street · 26.09.2026

• BeOne Medicines Advances Phase 3 Liver Cancer Trial With BGB-B2033 (öffnet in neuem Tab)

  TipRanks · 23.09.2026

• Sonrotoclax Safety Study Completion Signals Next Steps for BeOne Medicines (öffnet in neuem Tab)

  TipRanks · 21.09.2026

• ONC Q2 2026 Earnings: Reported EPS of $13.84 as Shares Edge Lower - Earnings Volatility Report (öffnet in neuem Tab)

  dars.gov.et · 21.09.2026

• BeOne Medicines (ONC) insiders exercise options for 30,768 ADS (öffnet in neuem Tab)

  Stock Titan · 18.09.2026

• BeOne Medicines at Morgan Stanley conference: brukinsa, pipeline drive growth (öffnet in neuem Tab)

  Investing.com UK · 14.09.2026

• The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal (öffnet in neuem Tab)

  Yahoo Finance · 04.09.2026

• BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It? (öffnet in neuem Tab)

  Yahoo Finance · 04.09.2026

• BeOne (ONC) accounting chief sells ADS to cover RSU taxes (öffnet in neuem Tab)

  Stock Titan · 03.09.2026

• BeOne Medicines (ONC) Holds Steady Near $362 Within Defined Trading Range - BPI Bear Correction (öffnet in neuem Tab)

  siam.in · 03.09.2026